Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $1.9 million.

  • Rocket Pharmaceuticals' Gains from Investment Securities was N/A to $3.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2024, which is 615.38% up from last year.
  • As of FY2024, Rocket Pharmaceuticals' Gains from Investment Securities stood at $1.9 million, which was up 615.38% from -$364,000 recorded in FY2023.
  • Rocket Pharmaceuticals' 5-year Gains from Investment Securities high stood at $26.6 million for FY2020, and its period low was -$364,000 during FY2023.
  • Moreover, its 2-year median value for Gains from Investment Securities was $756,000 (2023), whereas its average is $756,000.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Gains from Investment Securities surged by 7,632.56% in 2020 and then plummeted by 51.88% in 2021.
  • Rocket Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $26.6 million in 2020, then tumbled by 51.88% to $12.8 million in 2021, then reached -$364,000 in 2023, then skyrocketed by 615.38% to $1.9 million in 2024.